Rocket Lab: Less Euphoria, Still Too Much Perfection Priced In Ahead Of Q3

Rocket Lab has lost nearly 65% of its value since May, a decline the article attributes largely to excessive expectations and fading enthusiasm for space stocks rather than comparable deterioration in its business. The Neutron delay to 2027 and the $8 billion Iridium acquisition add execution and dilution risks, while the article cautions that investors may still be overpaying for growth years away.

Analysis

The key question is whether RKLB’s valuation still capitalizes successful Neutron commercialization while the company bears the cost and time risk before that revenue can exist. A schedule slip can have a second-order effect beyond deferred sales: customers may dual-source or award missions elsewhere, weakening future pricing and utilization even if the vehicle ultimately flies. Launch competitors could benefit at the margin, but the size of any share transfer depends on mission eligibility and available capacity—not simply the delay.

Treat the stated $8bn Iridium transaction as unverified until its status, scope, consideration and financing are confirmed. If accurate, the investment case changes materially: integration demands and any equity issuance could compete with Neutron funding and dilute per-share value; if the deal is not signed or the terms differ, that risk should not be priced as fact. Verify cash, debt, committed capex and pro forma share count before underwriting either scenario.

Near term, the sharp derating may already reflect some loss of space-sector enthusiasm, making an outright short vulnerable to a sentiment rebound. Over 1–3 months, financing terms, contract awards and milestone updates are the useful catalysts; over 6–18 months, flight readiness, customer conversion and capital intensity determine whether growth translates into per-share value. A contrarian case is that a delay is survivable if existing businesses fund development and Neutron retains customer demand, but no supplied data establish that cushion. Falsifiers for the cautious thesis: credible schedule recovery, funded deal terms with limited dilution, and contracted demand converting into demonstrable revenue/cash-flow progress.

Key Decisions for Investors

• Do not add solely because the share price has fallen. Keep RKLB underweight versus a diversified aerospace/space exposure until transaction terms and funding capacity are verified; avoid initiating an unhedged short after the large drawdown without valuation and borrow/positioning data.
• Set a diligence alert for signed acquisition documents, cash/debt and pro forma dilution, plus Neutron milestone changes and customer awards. If the acquisition is confirmed with material equity issuance or funding that crowds out development, reassess for a relative-value short versus XAR; if no binding deal exists, remove that deal-risk premium.
• For existing longs, size exposure against the possibility that schedule slippage delays customer cash flows and compounds dilution risk. Revisit only on evidence of schedule recovery and funded development—not promotional milestone language alone.
• Thesis check: reduce the underweight if RKLB demonstrates credible schedule recovery, limited dilution, and contracted demand translating into revenue or cash-flow progress; strengthen caution if guidance slips again or financing terms materially expand the share count.